Bis-anthracyclines with high activity against doxorubicin resistant tumors
US5874412A · kind A · utility
60Cited by
4References
25Claims
0Family size
Inventors
Key dates
| Filing date | Mar 21, 1997 |
| Grant date | Feb 23, 1999 |
| Priority date | — |
| Expiry date | Mar 21, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H15/252
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses new and novel bisanthracyclines linked through the saccharide portions. These compounds show high activity against two clinically relevant mechanisms of resistance. A novel approach of the invention produces compounds that are as active or more so than the parent compounds. Furthermore, the inventor's discovery is also for the design of effective DNA-binding bisanthracyclines as well as anthracyclines mixed with other intercalators and groove binders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.